Endothelial dysfunction in joint disease

Joint Bone Spine

Volumn 81, Issue 5, 2014, Pages 386-391

  Prati, Clément ^a,b   Demougeot, Céline ^b   Guillot, Xavier ^a   Godfrin Valnet, Marie ^a   Wendling, Daniel ^a,b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Endothelial dysfunction; Lupus; Rheumatoid arthritis; Spondyloarthritis

Indexed keywords

ACETYLCHOLINE; ADALIMUMAB; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; ARGINASE INHIBITOR; BIOLOGICAL PRODUCT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENZYME INHIBITOR; ETANERCEPT; GLUCOCORTICOID; GLYCERYL TRINITRATE; INFLIXIMAB; METHOTREXATE; N(G) NITROARGININE METHYL ESTER; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; QUINAPRIL; RAMIPRIL; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SIMVASTATIN; TOCILIZUMAB; UNCLASSIFIED DRUG;

ARTHRITIS; ARTHROPATHY; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC ARTHRITIS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; FLOW MEDIATED DILATION; FOREARM BLOOD FLOW; HUMAN; NONHUMAN; OPEN STUDY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION; POLYARTHRITIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SCLERODERMA; SHORT SURVEY; SJOEGREN SYNDROME; SPONDYLARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR ENDOTHELIUM; VASODILATATION; ATHEROSCLEROSIS; COMPLICATION; CONNECTIVE TISSUE DISEASE;

ARTHRITIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CONNECTIVE TISSUE DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; JOINT DISEASES;

EID: 84927698885     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.01.014     Document Type: Short Survey

References (60)

1. Bunting S., Gryglewski R., Moncada S., et al. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 1976, 12:897-913.
2. Sandoo A., Carroll D., Metsios G.S., et al. The association between microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2011, 13:R99.
3. Spasovski D., Latifi A., Osmani B., et al. Determination of the diagnostic values of asymmetric dimethylarginine as an indicator for evaluation of the endothelial dysfunction in patients with rheumatoid arthritis. Arthritis 2013, 2013:818037. 10.1155/2013/818037.
4. Bacon P.A., Raza K., Banks M.J., et al. The role of endothelial cell dysfunction in the cardiovascular mortality of RA. Int Rev Immunol 2002, 21:1-17.
5. Bergholm R., Leirisalo-Repo M., Vehkavaraa S., et al. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002, 1:1637-1641.
6. Chatterjee Adhikari M., Guin A., Chakraborty S., et al. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Semin Arthritis Rheum 2012, 41:669-675.
7. Södergren A., Karp K., Boman K., et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 2010, 12:R158.
8. Foster W., Lip G.Y., Raza K., et al. An observational study of endothelial function in early arthritis. Eur J Clin Invest 2012, 42:510-516.
9. Hürlimann D., Forster A., Noll G., et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002, 106:2184-2187.
10. Hänsel S., Lässig G., Pistrosch F., et al. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 2003, 170:177-180.
11. Irace C., Mancuso G., Fiaschi E., et al. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004, 177:113-118.
12. Gonzalez-Juanatey C., Testa A., Garcia-Castelo A., et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004, 51:447-450.
13. Bilsborough W., Keen H., Taylor A., et al. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 2006, 26:1125-1131.
14. Cardillo C., Schinzari F., Mores N., et al. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin Pharmacol Ther 2006, 80:275-281.
15. Mäki-Petäjä K.M., Hall F.C., Booth A.D., et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006, 114:1185-1192.
16. Bosello S., Santoliquido A., Zoli A., et al. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 2008, 27:833-839.
17. Ikonomidis I., Lekakis J.P., Nikolaou M., et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 2008, 117:2662-2669.
18. Gonzalez-Juanatey C., Llorca J., Vazquez-Rodriguez T.R., et al. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 2008, 59:1821-1824.
19. Sidiropoulos P.I., Siakka P., Pagonidis K., et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009, 38:6-10.
20. Kerekes G., Soltész P., Dér H., et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009, 28:705-710.
21. Capria A., De Nardo D., Baffetti F.R., et al. Long-term anti- TNF-alpha treatments reverse the endothelial dysfunction in rheumatoid arthritis: the biological coherence between synovial and endothelial inflammation. Int J Immunopathol Pharmacol 2010, 23:255-262.
22. Kerekes G., Soltész P., Szucs G., et al. Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. Isr Med Assoc J 2011, 13:147-152.
23. Protogerou A.D., Zampeli E., Fragiadaki K., et al. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 2011, 219:734-736.
24. Gonzalez-Juanatey C., Vazquez-Rodriguez T.R., Miranda-Filloy J.A., et al. Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. Mediators Inflamm 2012, 2012:674265. 10.1155/2012/674265.
25. Sandoo A., Kitas G.D., Carroll D., et al. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis Res Ther 2012, 14:R117.
26. Wong M., Jiang B.Y., McNeill K., et al. Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis. Scand J Rheumatol 2007, 36:265-269.
27. Hafström I., Rohani M., Deneberg S., et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis-a randomized study. J Rheumatol 2007, 34:1810-1816.
28. Veselinovic M.V., Zivkovic V.I., Toncev S., et al. Carotid artery intima-media thickness and brachial artery flow-mediated vasodilatation in patients with rheumatoid arthritis. Vasa 2012, 41:343-351.
29. Galarraga B., Belch J.J., Pullar T., et al. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy. J Rheumatol 2010, 37:521-528.
30. Kwaśny-Krochin B., Głuszko P., Undas A. Plasma asymmetric dimethylarginine in active rheumatoid arthritis: links with oxidative stress and inflammation. Pol Arch Med Wewn 2012, 122:270-276.
31. Di Franco M., Spinelli F.R., Metere A., et al. Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis. Mediators Inflamm 2012, 2012:347268. 10.1155/2012/347268.
32. Sandoo A., Dimitroulas T., Toms T.E., et al. Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis. Clin Biochem 2012, 45:1399-1403.
33. Turiel M., Tomasoni L., Sitia S., et al. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc Ther 2010, 28:53-64.
34. Hermann F., Forster A., Chenevard R., et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 2005, 45:461-464.
35. El-Barbary A.M., Hussein M.S., Rageh E.M., et al. Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. J Rheumatol 2011, 38:229-235.
36. Mäki-Petäjä K.M., Booth A.D., Hall F.C., et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007, 50:852-858.
37. Tikiz C., Utuk O., Pirildar T., et al. Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol 2005, 32:2095-2101.
38. Vaudo G., Marchesi S., Gerli R., et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004, 63:31-35.
39. Flammer A.J., Sudano I., Hermann F., et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 2008, 117:2262-2269.
40. Sandoo A., Veldhuijzen van Zanten J.J., Metsios G.S., et al. Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2011, 50:2125-2139.
41. Montecucco F., Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009, 48:11-22.
42. Hermann C., Assmus B., Urbich C., et al. Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 2000, 20:402-409.
43. Sari I., Okan T., Akar S., et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006, 45:283-286.
44. Kemény-Beke Á., Gesztelyi R., Bodnár N., et al. Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: association with other clinical and laboratory parameters. Joint Bone Spine 2011, 78:184-187.
45. Bodnár N., Kerekes G., Seres I., et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 2011, 38:723-729.
46. Erre G.L., Sanna P., Zinellu A., et al. Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study. Clin Rheumatol 2011, 30:21-27.
47. Syngle A., Vohra K., Sharma A., et al. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade. Clin Rheumatol 2010, 29:763-770.
48. Sari I., Kebapcilar L., Alacacioglu A., et al. Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis. Intern Med 2009, 48:1363-1368.
49. Atzeni F., Sarzi-Puttini P., Sitia S., et al. Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol 2011, 38:1661-1664.
50. Gonzalez-Juanatey C., Llorca J., Miranda-Filloy J.A., et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57:287-293.
51. Soltész P., Kerekes G., Dér H., et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev 2011, 10:416-425.
52. Szucs G., Timar O., Szekanecz Z., et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis-relevance for prevention of vascular complications. Rheumatology (Oxford) 2007, 46:759-762.
53. Akyel A., Tavil Y., Yayla C., et al. Endothelial dysfunction in primary Sjögren syndrome. West Indian Med J 2012, 61:870-872.
54. Pirildar T., Tikiz C., Ozkaya S., et al. Endothelial dysfunction in patients with primary Sjögren's syndrome. Rheumatol Int 2005, 25:536-539.
55. Fang Z.Y., Fontaine J., Unger P., et al. Alterations of the endothelial function of isolated aortae in rats with adjuvant arthritis. Arch Int Pharmacodyn Ther 1991, 311:122-130.
56. Egan C., Lockhart J., Ferrell W. Pathophysiology of vascular dysfunction in a rat model of chronic joint inflammation. J Physiol 2004, 1:635-643.
57. Ulker S., Onal A., Hatip F.B., et al. Effect of nabumetone treatment on vascular responses of the thoracic aorta in rat experimental arthritis. Pharmacology 2000, 60:136-142.
58. Haruna Y., Morita Y., Komai N., et al. Endothelial dysfunction in rat adjuvant-induced arthritis. Arthritis Rheum 2006, 54:1847-1855.
59. Prati C., Berthelot A., Wendling D., et al. Endothelial dysfunction in rat adjuvant-induced arthritis: up-regulation of the vascular arginase pathway. Arthritis Rheum 2011, 63:2309-2317.
60. Prati C., Berthelot A., Kantelip B., et al. Treatment with the arginase inhibitor Nw-hydroxy-nor-L-arginine restores endothelial function in rat adjuvant-induced arthritis. Arthritis Res Ther 2012, 14:R130.